Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings.

INTRODUCTION: Our aim was to investigate the prevalence of atrial fibrillation (AF) and recently diagnosed lung cancer in the outpatient oncology clinic and to describe the clinical profile, management and outcomes of this population.

METHODS: Among 6984 patients visited at the outpatient oncology clinics attending lung cancer patients in five university hospitals from 2017 to 2019, all consecutive subjects with recently diagnosed (<1 year) disease and AF were retrospectively selected and events in follow up were registered.

RESULTS: A total of 269 patients (3.9% of all attended, 71±8 years, 91% male) were included. Charlson, CHA2DS2-VASc and HAS-BLED indexes were 6.7±2.9, 2.9±1.5 y 2.5±1.2, respectively. Tumour stage was I, II, III and IV in 11%, 11%, 33% and 45% of them, respectively. Anticoagulants were prescribed to 226 patients (84%): direct anticoagulants (n=99;44%), low molecular weight heparins (n=69;30%) and vitamin K antagonists (n=58;26%). After 46 months of maximum follow-up, 186 patients died (69%). Cumulative incidences of events at 3 years were 3.3±1.3% for stroke/systemic embolism (n=7); 8.9±2.2% for thrombotic events (n=18); 9.9±2.6% for major bleeding (n=16), and 15.9±3,0% for cardiovascular events (n=33). In patients with early stages of cancer (I-II), 2-year mortality was significantly higher in those with cardiovascular events or major bleeding (85% vs 25%, p=0.01).

CONCLUSION: Nearly 4% or all outpatients in the oncology clinic attending lung cancer present recently diagnosed disease and AF. Major bleeding and cardiovascular event rates are high in this population, with an impact on mortality in early stages of cancer.